{
    "clinical_study": {
        "@rank": "139657", 
        "arm_group": [
            {
                "arm_group_label": "Volulyte 6%", 
                "arm_group_type": "Experimental", 
                "description": "- Volulyte 6% (HES 130/0.4 in an isotonic composition). In 1000 ml:\nMaize starch 60 gr. Molar substitution 0.38-0.45. 130000 Da\nNa acetate trihydrate 4.63 gr\nSodium Chloride 6.02 gr\nPotassium Chloride 0.3 gr\nMgCl 0.3 gr\nSodium hydroxide-hydrochloric acid & H2O"
            }, 
            {
                "arm_group_label": "Geloplasma", 
                "arm_group_type": "Active Comparator", 
                "description": "In 1000 ml:\nModified fluid gelatin 30 gr\nSodium Chloride 5.4 gr\nPotassium Chloride 0.37 gr\nMgCl 0.14 gr\nSodium lactate 3.36 gr"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this study is to compare 6% hydroxyethyl starch (HES) 130/0.4 in a balanced\n      electrolyte solution (Volulyte\u00ae) with modified fluid gelatin (Geloplasma\u00ae) as the priming\n      solution for the cardiopulmonary bypass (CPB) circuit. The microvascular reactivity and the\n      effects on tissue (StO2) and cerebral (ScO2) oxygen saturation will be examined using\n      near-infrared spectroscopy (NIRS)."
        }, 
        "brief_title": "The Effect of Hydroxyethylstarch 6% 130/0.4 in a Balanced Electrolyte Solution (Volulyte\u00ae) Compared to Gelatine (Geloplasma\u00ae) on Microvascular Reactivity and Tissue Oxygen Saturation During Haemodilution Measured With Near-infrared Spectroscopy", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Microvascular Reactivity", 
            "Tissue Oxygen Saturation"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Adult consenting patients scheduled for elective coronary artery bypass grafting surgery\n        on moderately hypothermic (> 32\u00b0C) CPB without blood transfusion. Age \u2265 18 years.\n\n        Exclusion Criteria:\n\n        Exclusion criteria are an ejection fraction < 25%, a known allergy to HES, admission of\n        HES or gelatines within the preceding 2 weeks, renal insufficiency (creatinine > 2.0\n        mg/dl), significant hepatic disease (liver function tests > 3x upper limit of normal),\n        history of cerebrovascular disease, significant carotid artery stenosis (> 60%),\n        perioperative use of corticosteroids, and need for vasopressor or inotropic therapy before\n        surgery. An expected haematocrit on CPB, calculated based on preoperative haematocrit,\n        calculated blood volume and amount of cardioplegia, of < 23% is also considered an\n        exclusion criterium"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02034682", 
            "org_study_id": "2013/1085", 
            "secondary_id": "2013-005209-30"
        }, 
        "intervention": [
            {
                "arm_group_label": "Volulyte 6%", 
                "description": "During elective coronary artery bypass grafting surgery, patients need to be attached to a cardiopulmonary bypass circuit. Administration of Volulyte 6% to the cardiopulmonary bypass circuit.", 
                "intervention_name": "Volulyte 6%", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Geloplasma", 
                "description": "During elective coronary artery bypass grafting surgery, patients need to be attached to a cardiopulmonary bypass circuit. Administration of Geloplasma to the cardiopulmonary bypass circuit.", 
                "intervention_name": "Geloplasma", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Hetastarch", 
                "Citric Acid"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 10, 2014", 
        "link": {
            "url": "http://www.uzgent.be"
        }, 
        "location": {
            "contact": {
                "email": "Annelies.Moerman@ugent.be", 
                "last_name": "Annelies Moerman, MD, PhD"
            }, 
            "facility": {
                "address": {
                    "city": "Ghent", 
                    "country": "Belgium", 
                    "zip": "9000"
                }, 
                "name": "Ghent University Hospital"
            }, 
            "investigator": {
                "last_name": "Annelies Moerman, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Effect of Hydroxyethylstarch 6% 130/0.4 in a Balanced Electrolyte Solution (Volulyte\u00ae) Compared to Gelatine (Geloplasma\u00ae) on Microvascular Reactivity and Tissue Oxygen Saturation During Haemodilution Measured With Near-infrared Spectroscopy", 
        "overall_contact": {
            "email": "Annelies.Moerman@ugent.be", 
            "last_name": "Annelies Moerman, MD, PhD"
        }, 
        "overall_official": {
            "affiliation": "Ghent University Hospital", 
            "last_name": "Annelies Moerman, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Belgium: Ethics Committee", 
                "Belgium: Federal Agency for Medicinal Products and Health Products"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Values are measured, using near-infrared spectroscopy.", 
            "measure": "Value of the StO2 recovery slope (recStO2) after postocclusive ischaemia.", 
            "safety_issue": "No", 
            "time_frame": "after 3 minutes of postocclusive ischaemia"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02034682"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change of values of ScO2 during cardiopulmonary bypass (CPB ).", 
                "safety_issue": "No", 
                "time_frame": "Continuously during cardiopulmonary bypass (= maximum 3 hours)."
            }, 
            {
                "measure": "Change of value of StO2 during cardiopulmonary bypass.", 
                "safety_issue": "No", 
                "time_frame": "Continuously during cardiopulmonary bypass(= maximum 3 hours)."
            }, 
            {
                "measure": "Change of blood gas analyses during cardiopulmonary bypass.", 
                "safety_issue": "No", 
                "time_frame": "Continuously during cardiopulmonary bypass(= maximum 3 hours)."
            }, 
            {
                "measure": "Change of haemodynamics during cardiopulmonary bypass.", 
                "safety_issue": "No", 
                "time_frame": "Continuously during cardiopulmonary bypass(= maximum 3 hours)."
            }, 
            {
                "measure": "Urinary output during cardiopulmonary bypass.", 
                "safety_issue": "No", 
                "time_frame": "At the end of cardiopulmonary bypass(= after maximum 3 hours).."
            }, 
            {
                "measure": "Use of vasoactive medication during cardiopulmonary bypass.", 
                "safety_issue": "No", 
                "time_frame": "During complete cardiopulmonary bypass(= maximum 3 hours)."
            }
        ], 
        "source": "University Hospital, Ghent", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University Hospital, Ghent", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}